Gene Analysis (v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog), Targeted Sequence in Florida
Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.
Top Providers in Florida
| Provider | Medicare | Services |
|---|---|---|
| Hematopathology Associates Llc | $322.92 | 1.4K |
| Southern Quest Llc | $322.92 | 1.1K |
| Biogroup Laboratory Corp | $322.92 | 1.1K |
| Sm Diagnostics Llc | $322.92 | 262 |
| Neogenomics Laboratories Inc | $322.92 | 134 |
| Precheck Health Services Inc | $322.92 | 104 |
| Molecular Clinical Laboratory, Inc | $322.92 | 44 |
| Quest Diagnostics Clinical... | $322.92 | 20 |
Florida Pricing in Context
In Florida, CPT code 81272 (Gene Analysis (v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog), Targeted Sequence) carries an average Medicare payment of $322.92 — 0% above the national benchmark of $322.54. 13 providers across the state submitted claims for this procedure in 2023, performing 4.2K total services. Individual payments in FL ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.
The average billed charge in Florida is $364.55, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Florida sits above the national Medicare average, commercial rates in the state may also run higher than the US median.
Using RAND 2024 commercial-to-Medicare ratios for Genetic/Molecular Test procedures, the estimated commercial insurance price in Florida lands near $758.86, with self-pay cash prices typically around $342.44. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.
Frequently Asked Questions
How much does Gene Analysis (v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog), Targeted Sequence cost in Florida?
The average Medicare payment for Gene Analysis (v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog), Targeted Sequence in Florida is $322.92, which is 0% above the national average of $322.54. Providers in FL typically bill $364.55 for this procedure.
What does Gene Analysis (v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog), Targeted Sequence cost with insurance in Florida?
With commercial insurance in Florida, Gene Analysis (v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog), Targeted Sequence costs an estimated $758.86. Without insurance, the estimated cash price is $342.44. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.
How many providers perform Gene Analysis (v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog), Targeted Sequence in Florida?
13 providers in Florida billed Medicare for Gene Analysis (v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog), Targeted Sequence in 2023, performing 4.2K total services. Medicare payments ranged from N/A to N/A depending on the provider.
Is Gene Analysis (v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog), Targeted Sequence cheaper in Florida than the national average?
No — Gene Analysis (v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog), Targeted Sequence costs 0% above the national average in Florida. The state average Medicare payment is $322.92 compared to $322.54 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.
Related Guides
Related Data Sources
Data from CMS Medicare Physician & Other Practitioners (2023).
Read our methodology — how this data is sourced, computed, and verified.